16,702 Shares in Prothena Corporation plc $PRTA Acquired by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC acquired a new position in shares of Prothena Corporation plc (NASDAQ:PRTA) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 16,702 shares of the biotechnology company’s stock, valued at approximately $101,000.

Several other hedge funds have also made changes to their positions in the company. Wellington Management Group LLP grew its position in shares of Prothena by 1.3% during the 1st quarter. Wellington Management Group LLP now owns 5,199,528 shares of the biotechnology company’s stock worth $64,344,000 after buying an additional 68,652 shares in the last quarter. Siren L.L.C. raised its holdings in shares of Prothena by 16.7% in the first quarter. Siren L.L.C. now owns 1,283,555 shares of the biotechnology company’s stock valued at $15,884,000 after acquiring an additional 183,715 shares in the last quarter. Birchview Capital LP lifted its stake in Prothena by 9.3% in the first quarter. Birchview Capital LP now owns 332,974 shares of the biotechnology company’s stock worth $4,121,000 after acquiring an additional 28,400 shares during the period. Nordea Investment Management AB grew its holdings in Prothena by 1.2% during the 2nd quarter. Nordea Investment Management AB now owns 311,605 shares of the biotechnology company’s stock worth $1,916,000 after acquiring an additional 3,618 shares in the last quarter. Finally, DCF Advisers LLC increased its position in Prothena by 88.4% during the 1st quarter. DCF Advisers LLC now owns 195,000 shares of the biotechnology company’s stock valued at $2,413,000 after purchasing an additional 91,500 shares during the period. 97.08% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on PRTA shares. Royal Bank Of Canada upped their price target on shares of Prothena from $10.00 to $11.00 and gave the stock a “sector perform” rating in a research report on Friday, November 7th. Wall Street Zen upgraded Prothena from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. HC Wainwright lifted their price target on Prothena from $20.00 to $30.00 and gave the company a “buy” rating in a report on Friday, November 7th. Piper Sandler upped their price objective on Prothena from $15.00 to $36.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 28th. Finally, JMP Securities dropped their price objective on Prothena from $29.00 to $11.00 and set a “market outperform” rating on the stock in a research report on Tuesday, September 2nd. Four research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Prothena currently has a consensus rating of “Hold” and an average target price of $25.78.

Prothena Trading Up 1.1%

Shares of PRTA opened at $10.36 on Wednesday. The firm has a market cap of $557.68 million, a PE ratio of -1.84 and a beta of -0.09. Prothena Corporation plc has a 12 month low of $4.32 and a 12 month high of $17.66. The stock has a fifty day moving average price of $9.77 and a 200-day moving average price of $7.85.

Prothena (NASDAQ:PRTA) last announced its earnings results on Thursday, November 6th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Prothena had a negative return on equity of 62.17% and a negative net margin of 2,929.30%.The business had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $6.64 million. As a group, research analysts forecast that Prothena Corporation plc will post -4.04 EPS for the current year.

Prothena Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.